Evidence map›Paper›PMID 33578751›Full record

ReviewCells2021

New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking.

Mourad Zerfaoui, Titilope Modupe Dokunmu, Eman Ali Toraih, Bashir M Rezk, Zakaria Y Abd Elmageed, Emad Kandil

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Is Melanoma Progression Affected by Thyroid Diseases?International journal of molecular sciences · 2022
    Review
  10. Nuclear interaction of Arp2/3 complex and BRAFAmerican journal of cancer research · 2022
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Mourad ZerfaouiDepartment of Surgery, Tulane University School of Medicine, 1430 Tulane Avenue, SL-22 New Orleans, LA 70112, USA.
Titilope Modupe DokunmuDepartment of Surgery, Tulane University School of Medicine, 1430 Tulane Avenue, SL-22 New Orleans, LA 70112, USA.ORCID 0000-0002-8751-3436
Eman Ali ToraihDepartment of Surgery, Tulane University School of Medicine, 1430 Tulane Avenue, SL-22 New Orleans, LA 70112, USA.ORCID 0000-0001-9267-3787
Bashir M RezkDepartment of Natural Sciences, Biology Unit, Southern University at New Orleans, New Orleans, LA 70126, USA.
Zakaria Y Abd ElmageedDepartment of Pharmacology, Edward Via College of Osteopathic Medicine, University of Louisiana at Monroe, Monroe, LA 71203, USA.ORCID 0000-0003-4031-0348
Emad KandilDepartment of Surgery, Tulane University School of Medicine, 1430 Tulane Avenue, SL-22 New Orleans, LA 70112, USA.
Tulane University · USSouthern University at New Orleans · USUniversity of Louisiana at Monroe · US

Funding

Carol Lavin Bernick Faculty Grant 631465
6 · The paper itself

Abstract

Cancer remains a major public health concern, mainly because of the incompletely understood dynamics of molecular mechanisms for progression and resistance to treatments. The link between melanoma and thyroid cancer (TC) has been noted in numerous patients. Nucleocytoplasmic transport of oncogenes and tumor suppressor proteins is a common mechanism in melanoma and TC that promotes tumorigenesis and tumor aggressiveness. However, this mechanism remains poorly understood. Papillary TC (PTC) patients have a 1.8-fold higher risk for developing cutaneous malignant melanoma than healthy patients. Our group and others showed that patients with melanoma have a 2.15 to 2.3-fold increased risk of being diagnosed with PTC. The

Indexed as

Active Transport, Cell NucleusAnimalsCell NucleusDrug Resistance, NeoplasmHumansMelanomaRisk FactorsThyroid NeoplasmsBRAF V600Emelanomanucleocytoplasmic transportresistancethyroid cancertumor aggressiveness

Identifiers

PMID33578751
PMCPMC7916461
OpenAlexW3128111499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.